MA45784A - Anticorps anti-idiotypes dirigés contre anti-cd19 anticorps - Google Patents
Anticorps anti-idiotypes dirigés contre anti-cd19 anticorpsInfo
- Publication number
- MA45784A MA45784A MA045784A MA45784A MA45784A MA 45784 A MA45784 A MA 45784A MA 045784 A MA045784 A MA 045784A MA 45784 A MA45784 A MA 45784A MA 45784 A MA45784 A MA 45784A
- Authority
- MA
- Morocco
- Prior art keywords
- antibody
- directed against
- idiotypes
- idiotypes directed
- body anti
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
- C07K16/4258—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/686—Anti-idiotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662369008P | 2016-07-29 | 2016-07-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA45784A true MA45784A (fr) | 2019-06-05 |
Family
ID=59656185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA045784A MA45784A (fr) | 2016-07-29 | 2017-07-29 | Anticorps anti-idiotypes dirigés contre anti-cd19 anticorps |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240018268A1 (fr) |
| EP (1) | EP3491024B1 (fr) |
| JP (2) | JP7062640B2 (fr) |
| KR (2) | KR102553195B1 (fr) |
| CN (2) | CN110088133B (fr) |
| AU (1) | AU2017301887A1 (fr) |
| BR (1) | BR112019001327A2 (fr) |
| CA (1) | CA3031734A1 (fr) |
| ES (1) | ES3004039T3 (fr) |
| MA (1) | MA45784A (fr) |
| MX (1) | MX2019001184A (fr) |
| WO (1) | WO2018023100A2 (fr) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018013563A1 (fr) | 2016-07-12 | 2018-01-18 | Kite Pharma, Inc. | Molécules de liaison à l'antigène et procédés d'utilisation associés |
| WO2018023100A2 (fr) * | 2016-07-29 | 2018-02-01 | Juno Therapeutics, Inc. | Anticorps anti-idiotypes et procédés associés |
| EP4538295A3 (fr) | 2016-09-28 | 2025-06-18 | Kite Pharma, Inc. | Molécules de liaison à l'antigène et leurs procédés d'utilisation |
| CN110382696B (zh) * | 2017-03-07 | 2024-04-19 | 豪夫迈·罗氏有限公司 | 发现替代性抗原特异性抗体变体的方法 |
| KR20200064060A (ko) * | 2017-07-29 | 2020-06-05 | 주노 쎄러퓨티크스 인코퍼레이티드 | 재조합 수용체를 발현하는 세포 증폭용 시약 |
| WO2019089798A1 (fr) * | 2017-10-31 | 2019-05-09 | Novartis Ag | Compositions anti-car et procédés |
| CN108508200B (zh) * | 2018-04-18 | 2023-12-22 | 上海星湾生物技术有限公司 | 检测表达cd19 car的细胞的方法及其应用 |
| CA3117978A1 (fr) | 2018-11-08 | 2020-05-14 | Juno Therapeutics, Inc. | Procedes et combinaisons pour le traitement et la modulation de lymphocytes t |
| GB201820444D0 (en) * | 2018-12-14 | 2019-01-30 | Adaptimmune Ltd | Marker for T cell expansion |
| CN111349161B (zh) * | 2018-12-20 | 2022-02-08 | 上海星湾生物技术有限公司 | 抗cd19抗体的单克隆抗体及其应用 |
| MX2021012726A (es) * | 2019-04-19 | 2021-11-17 | Allogene Therapeutics Inc | Anticuerpos contra receptores de antigenos quimericos derivados de 4g7. |
| AU2020334237B2 (en) * | 2019-08-19 | 2025-11-13 | Universität Basel | Cell therapy methods |
| WO2021084050A1 (fr) | 2019-10-30 | 2021-05-06 | Juno Therapeutics Gmbh | Dispositifs de sélection et/ou stimulation de cellules et procédés d'utilisation |
| IL292667B1 (en) | 2019-11-07 | 2026-02-01 | Juno Therapeutics Inc | Combination of T-cell therapy and (s)-3-[4-(4-morpholin-4-ylmethyl-benzyloxy)-l-oxo-3,l-dihydro-isoindol-2-yl]-piperidine-6,2-dione |
| WO2021100585A1 (fr) * | 2019-11-20 | 2021-05-27 | 国立大学法人東海国立大学機構 | Procédé de production de lymphocytes modifiés par un gène récepteur d'antigène chimère |
| CN110894238B (zh) * | 2019-11-25 | 2021-01-19 | 华道(上海)生物医药有限公司 | Car-t细胞的检测用单克隆抗体、试剂盒及应用 |
| AU2021221277A1 (en) * | 2020-02-11 | 2022-08-25 | Crispr Therapeutics Ag | Anti-idiotype antibodies targeting anti-CD19 chimeric antigen receptor |
| WO2022003158A1 (fr) * | 2020-07-03 | 2022-01-06 | Cellectis S.A. | Procédé de détermination de la puissance d'un récepteur d'antigène chimérique exprimant des cellules immunitaires |
| JP7844430B2 (ja) * | 2020-07-17 | 2026-04-13 | ヤンセン バイオテツク，インコーポレーテツド | 抗ｇｐｒｃ５ｄ抗体に対する抗イディオタイプ抗体 |
| EP4182353A1 (fr) * | 2020-07-17 | 2023-05-24 | Janssen Biotech, Inc. | Anticorps anti-idiotypiques dirigés contre des anticorps anti-klk2 |
| CN112143707A (zh) * | 2020-09-29 | 2020-12-29 | 广东先康达生物科技有限公司 | 一种治疗自身免疫细胞的免疫细胞及其应用 |
| WO2022098787A1 (fr) | 2020-11-04 | 2022-05-12 | Juno Therapeutics, Inc. | Cellules exprimant un récepteur chimérique à partir d'un locus de chaîne de la superfamille des immunoglobines cd3 invariable modifié, polynucléotides et procédés associés |
| JP2024500847A (ja) * | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス，インコーポレイテッド | 適合可能な受容体特異性を有するキメラ抗原受容体システム |
| WO2022187406A1 (fr) | 2021-03-03 | 2022-09-09 | Juno Therapeutics, Inc. | Combinaison d'une thérapie par lymphocytes t et d'un inhibiteur de dgk |
| US20240150712A1 (en) * | 2021-03-17 | 2024-05-09 | Miltenyi Biotec B.V. & Co Kg | Artificial target for antigen-specific activation and expansion of car t cells |
| KR20230158573A (ko) | 2021-03-22 | 2023-11-20 | 주노 쎄러퓨티크스 인코퍼레이티드 | 바이러스 벡터 입자의 효력을 평가하는 방법 |
| KR20230159851A (ko) | 2021-03-22 | 2023-11-22 | 주노 쎄러퓨티크스 인코퍼레이티드 | 치료 세포 조성물의 효력을 결정하는 방법 |
| AU2022252220A1 (en) | 2021-03-29 | 2023-10-12 | Juno Therapeutics, Inc. | Combination of a car t cell therapy and an immunomodulatory compound for treatment of lymphoma |
| JP2024517863A (ja) | 2021-05-06 | 2024-04-23 | ジュノ・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 細胞を刺激し、形質導入する方法 |
| TW202321311A (zh) * | 2021-08-02 | 2023-06-01 | 日商諾伊爾免疫生物科技股份有限公司 | 與scFv等之連接子結合的抗體 |
| EP4698902A1 (fr) | 2023-04-18 | 2026-02-25 | Juno Therapeutics, Inc. | Essai cytotoxique pour évaluer la puissance de compositions de cellules thérapeutiques |
| WO2024226858A1 (fr) | 2023-04-26 | 2024-10-31 | Juno Therapeutics, Inc. | Procédés de fabrication de vecteurs viraux |
| EP4716851A2 (fr) | 2023-05-23 | 2026-04-01 | Juno Therapeutics, Inc. | Marqueurs d'activation de lymphocytes t et procédé d'évaluation de l'activation de lymphocytes t |
| WO2025005938A1 (fr) * | 2023-06-26 | 2025-01-02 | Memorial Sloan-Kettering Cancer Center | Anticorps et fragments de liaison à l'antigène de ceux-ci se liant à des récepteurs chimériques et leurs utilisations |
| CN121729430A (zh) * | 2023-10-11 | 2026-03-24 | 合肥安博宁生命科技有限公司 | 抗cd3可激活抗体及其用途 |
| WO2025117639A1 (fr) * | 2023-11-27 | 2025-06-05 | Profoundbio Us Co. | Anticorps et procédés de détection de ptk7 |
| WO2025235727A1 (fr) * | 2024-05-08 | 2025-11-13 | Interius Biotherapeutics, Inc. | Dosage du titrage infectieux |
| WO2026020055A2 (fr) | 2024-07-18 | 2026-01-22 | Juno Therapeutics, Inc. | Procédés d'évaluation d'exosomes dans une composition cellulaire et utilisations associées |
| WO2026064719A1 (fr) * | 2024-09-22 | 2026-03-26 | Allogene Therapeutics, Inc. | Anticorps anti-idiotypiques cd19 |
Family Cites Families (107)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4452773A (en) | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4795698A (en) | 1985-10-04 | 1989-01-03 | Immunicon Corporation | Magnetic-polymer particles |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| EP0307434B2 (fr) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Anticorps alteres |
| US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
| US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ES2067018T3 (es) | 1988-12-28 | 1995-03-16 | Stefan Miltenyi | Procedimiento y materiales para la separacion en alto gradiente magnetico de materiales biologicos. |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| CA2026147C (fr) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Agents cytotoxiques comprenant des maytansinoides et leur usage therapeutique |
| US5200084A (en) | 1990-09-26 | 1993-04-06 | Immunicon Corporation | Apparatus and methods for magnetic separation |
| ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
| DE69303494T2 (de) | 1992-11-13 | 1997-01-16 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| EP0814838B1 (fr) | 1995-03-08 | 2003-05-14 | The Scripps Research Institute | Systeme de presentation des antigenes pour l'activation des lymphocytes t |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| DE19608753C1 (de) | 1996-03-06 | 1997-06-26 | Medigene Gmbh | Transduktionssystem und seine Verwendung |
| WO1997034634A1 (fr) | 1996-03-20 | 1997-09-25 | Sloan-Kettering Institute For Cancer Research | Produits de recombinaison d'anticorps diriges contre le gd2, constitues d'un fragment variable (fv) a chaine simple |
| AU6467796A (en) | 1996-04-24 | 1997-05-15 | Claude Fell | Cell separation system for biological fluids like blood |
| AU723355B2 (en) | 1996-05-23 | 2000-08-24 | Scripps Research Institute, The | MHC class II antigen presenting systems and methods for activating CD4+ T cells |
| US5837283A (en) | 1997-03-12 | 1998-11-17 | The Regents Of The University Of California | Cationic lipid compositions targeting angiogenic endothelial cells |
| CA2293829C (fr) | 1997-06-24 | 2011-06-14 | Genentech, Inc. | Procedes et compositions concernant des glycoproteines galactosylees |
| DE69840412D1 (de) | 1997-10-31 | 2009-02-12 | Genentech Inc | Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen |
| ES2375931T3 (es) | 1997-12-05 | 2012-03-07 | The Scripps Research Institute | Humanización de anticuerpo murino. |
| AU3657899A (en) | 1998-04-20 | 1999-11-08 | James E. Bailey | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| WO2000014257A1 (fr) | 1998-09-04 | 2000-03-16 | Sloan-Kettering Institute For Cancer Research | Recepteurs de fusion specifiques a l'antigene prostatique specifique membranaire et ses utilisations |
| AU2472400A (en) | 1998-10-20 | 2000-05-08 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| CN1182882C (zh) | 1998-12-24 | 2005-01-05 | 生物安全股份有限公司 | 特别用于浓缩造血干细胞的血液分离系统 |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6790662B1 (en) | 1999-03-12 | 2004-09-14 | Ortho-Mcneil Pharmaceutical, Inc. | Method of isolating CD8+ cells, and related hybridoma cells antibodies and polypeptides |
| PT1176195E (pt) | 1999-04-09 | 2013-07-18 | Kyowa Hakko Kirin Co Ltd | Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico |
| CA2388245C (fr) | 1999-10-19 | 2012-01-10 | Kyowa Kirin Co., Ltd. | L'utilisation de cellules de rat adaptess exemptes de serum pour produire de polypeptides heterologues |
| ES2274823T3 (es) | 1999-12-29 | 2007-06-01 | Immunogen, Inc. | Agentes cototoxicos que comprenden doxorrubicinas y daunorrubicinas y su utilizacion terapeutica. |
| US20040005561A1 (en) * | 2000-03-01 | 2004-01-08 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| CA2410510A1 (fr) | 2000-06-02 | 2001-12-13 | Memorial Sloan-Kettering Cancer Center | Cellules presentatrices d'antigene artificiel et leurs methodes d'utilisation |
| DK2314686T4 (da) | 2000-10-06 | 2023-08-21 | Kyowa Kirin Co Ltd | Celler, der danner antistofsammensætninger |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| AU2001297703B2 (en) | 2000-11-07 | 2006-10-19 | City Of Hope | CD19-specific redirected immune cells |
| US20040071671A1 (en) | 2001-02-20 | 2004-04-15 | Leturcq Didier J. | Cell therapy method for the treatment of tumors |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| NZ581474A (en) | 2001-08-03 | 2011-04-29 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| KR100988949B1 (ko) | 2001-10-25 | 2010-10-20 | 제넨테크, 인크. | 당단백질 조성물 |
| US7939059B2 (en) | 2001-12-10 | 2011-05-10 | California Institute Of Technology | Method for the generation of antigen-specific lymphocytes |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| CA2481837A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Procede de production de composition anticorps |
| AU2003236017B2 (en) | 2002-04-09 | 2009-03-26 | Kyowa Kirin Co., Ltd. | Drug containing antibody composition |
| US20040259150A1 (en) | 2002-04-09 | 2004-12-23 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa |
| US20040110704A1 (en) | 2002-04-09 | 2004-06-10 | Kyowa Hakko Kogyo Co., Ltd. | Cells of which genome is modified |
| AU2003236020B2 (en) | 2002-04-09 | 2009-03-19 | Kyowa Hakko Kirin Co., Ltd. | Cell with depression or deletion of the activity of protein participating in GDP-fucose transport |
| EP1502603A4 (fr) | 2002-04-09 | 2006-12-13 | Kyowa Hakko Kogyo Kk | MEDICAMENT CONTENANT UNE COMPOSITION D'ANTICORPS APPROPRIEE AU PATIENT SOUFFRANT DE POLYMORPHISME FC gammma RIIIA |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| EP1944320A1 (fr) | 2002-12-16 | 2008-07-16 | Genentech, Inc. | Variantes de l'immunoglobuline et leurs utilisations |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| AU2004279742A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Fused protein composition |
| JPWO2005035778A1 (ja) | 2003-10-09 | 2006-12-21 | 協和醗酵工業株式会社 | α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法 |
| EP1673395A1 (fr) | 2003-10-15 | 2006-06-28 | PDL BioPharma, Inc. | Modification de demi-vies seriques de proteines de fusion fc par mutagenese de positions 250, 314 et/ou 428 de la region constante de la chaine lourde des immunoglobulines |
| ES2393555T3 (es) | 2003-10-22 | 2012-12-26 | Keck Graduate Institute | Métodos para la síntesis de polipéptidos hetero-multiméricos en levaduras usando una estrategia de apareamiento haploide. |
| PT1692182E (pt) | 2003-11-05 | 2010-05-13 | Roche Glycart Ag | Anticorpos de cd20 com uma afinidade de ligação acrescida ao receptor fc e uma função efectora acrescida |
| EP3434275A1 (fr) | 2003-11-06 | 2019-01-30 | Seattle Genetics, Inc. | Méthode de dépistage de cellules cancéreuses basé sur l'utilisation de conjugués d'auristatin avec anticorps |
| JPWO2005053742A1 (ja) | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
| CA2568344C (fr) | 2004-05-27 | 2016-01-19 | The Trustees Of The University Of Pennsylvania | Cellules de presentation de nouveaux antigenes artificiels, et utilisations correspondantes |
| ES2579805T3 (es) | 2004-09-23 | 2016-08-16 | Genentech, Inc. | Anticuerpos y conjugados modificados por ingeniería genética con cisteína |
| US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| ES2345837T3 (es) | 2005-03-23 | 2010-10-04 | Biosafe S.A. | Sistema integrado para la recogida, el procesamiento y el trasplante de subgrupos de celulas, incluyendo celulas madre adultas, para medicina regenerativa. |
| US7993638B2 (en) | 2006-03-01 | 2011-08-09 | Janssen Pharmaceutica Nv | Cancer treatment combining lymphodepleting agent with CTLs and cytokines |
| CA2665568C (fr) | 2006-10-04 | 2018-01-09 | Janssen Pharmaceutica, N.V. | Preparation de cellules presentant l'antigene artificielles inactivees et leur utilisation dans des therapies cellulaires |
| EP2064335A4 (fr) | 2006-10-16 | 2011-03-30 | Medimmune Llc | Molécules ayant des demi-vies réduites, compositions et leurs utilisations |
| PL2856876T3 (pl) | 2007-03-30 | 2018-06-29 | Memorial Sloan-Kettering Cancer Center | Konstytutywna ekspresja ligandów kostymulujących na limfocytach T poddanych transferowi adoptywnemu |
| ES2640216T3 (es) | 2007-12-07 | 2017-11-02 | Miltenyi Biotec Gmbh | Sistemas y métodos para procesamiento de células |
| US8479118B2 (en) | 2007-12-10 | 2013-07-02 | Microsoft Corporation | Switching search providers within a browser search box |
| US20120164718A1 (en) | 2008-05-06 | 2012-06-28 | Innovative Micro Technology | Removable/disposable apparatus for MEMS particle sorting device |
| JP5173594B2 (ja) | 2008-05-27 | 2013-04-03 | キヤノン株式会社 | 管理装置、画像形成装置及びそれらの処理方法 |
| US8822647B2 (en) | 2008-08-26 | 2014-09-02 | City Of Hope | Method and compositions using a chimeric antigen receptor for enhanced anti-tumor effector functioning of T cells |
| ES2717629T3 (es) | 2009-11-03 | 2019-06-24 | Hope City | Receptor del factor de crecimiento epidérmico truncado (EGFRt) para selección de células T transducidas |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| US9987308B2 (en) | 2011-03-23 | 2018-06-05 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| US8398282B2 (en) | 2011-05-12 | 2013-03-19 | Delphi Technologies, Inc. | Vehicle front lighting assembly and systems having a variable tint electrowetting element |
| US10208086B2 (en) | 2011-11-11 | 2019-02-19 | Fred Hutchinson Cancer Research Center | Cyclin A1-targeted T-cell immunotherapy for cancer |
| EP3594245A1 (fr) | 2012-02-13 | 2020-01-15 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Récepteurs d'antigènes chimériques bispécifiques et leurs utilisations thérapeutiques |
| WO2013126726A1 (fr) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Lymphocytes t doubles transgéniques comportant un car et un tcr, et leurs procédés d'utilisation |
| JP6362543B2 (ja) | 2012-02-23 | 2018-07-25 | ジュノ セラピューティクス ゲーエムベーハー | 細胞および他の複雑な生物学的材料のクロマトグラフィーによる単離 |
| CN107557334B (zh) | 2012-05-03 | 2021-06-25 | 弗雷德哈钦森癌症研究中心 | 增强亲和力的t细胞受体及其制备方法 |
| US20150290244A1 (en) | 2012-07-13 | 2015-10-15 | The Trustees Of The University Of Pennsylvania | Use of cart19 to deplete normal b cells to induce tolerance |
| PL3824905T3 (pl) | 2012-08-20 | 2025-05-05 | Fred Hutchinson Cancer Center | Sposób i kompozycje do immunoterapii komórkowej |
| SG11201502598SA (en) | 2012-10-02 | 2015-05-28 | Sloan Kettering Inst Cancer | Compositions and methods for immunotherapy |
| JP5372297B1 (ja) | 2012-12-20 | 2013-12-18 | 三菱電機株式会社 | 車載装置及びプログラム |
| BR112015020516A2 (pt) | 2013-02-26 | 2017-10-10 | Memorial Sloan Kettering Cancer Center | composições e métodos para imunoterapia |
| US20160145348A1 (en) | 2013-03-14 | 2016-05-26 | Fred Hutchinson Cancer Research Center | Compositions and methods to modify cells for therapeutic objectives |
| TWI654206B (zh) | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症 |
| WO2014190273A1 (fr) | 2013-05-24 | 2014-11-27 | Board Of Regents, The University Of Texas System | Anticorps monoclonaux ciblant un récepteur d'antigène chimérique |
| US9108442B2 (en) | 2013-08-20 | 2015-08-18 | Ricoh Company, Ltd. | Image forming apparatus |
| LT3132247T (lt) | 2014-04-16 | 2021-12-10 | Juno Therapeutics Gmbh | Ląstelių populiacijos padauginimo būdai, rinkiniai ir priemonės |
| CN113736828A (zh) | 2014-11-05 | 2021-12-03 | 朱诺治疗学股份有限公司 | 用于转导及细胞处理的方法 |
| WO2017015427A1 (fr) | 2015-07-21 | 2017-01-26 | Novartis Ag | Méthodes pour améliorer l'efficacité et l'expansion de cellules immunitaires |
| WO2018023100A2 (fr) * | 2016-07-29 | 2018-02-01 | Juno Therapeutics, Inc. | Anticorps anti-idiotypes et procédés associés |
-
2017
- 2017-07-29 WO PCT/US2017/044560 patent/WO2018023100A2/fr not_active Ceased
- 2017-07-29 BR BR112019001327-0A patent/BR112019001327A2/pt not_active IP Right Cessation
- 2017-07-29 CA CA3031734A patent/CA3031734A1/fr active Pending
- 2017-07-29 MX MX2019001184A patent/MX2019001184A/es unknown
- 2017-07-29 MA MA045784A patent/MA45784A/fr unknown
- 2017-07-29 CN CN201780059515.0A patent/CN110088133B/zh active Active
- 2017-07-29 AU AU2017301887A patent/AU2017301887A1/en not_active Abandoned
- 2017-07-29 JP JP2019504855A patent/JP7062640B2/ja not_active Expired - Fee Related
- 2017-07-29 KR KR1020197006113A patent/KR102553195B1/ko active Active
- 2017-07-29 US US16/320,077 patent/US20240018268A1/en not_active Abandoned
- 2017-07-29 EP EP17754531.6A patent/EP3491024B1/fr active Active
- 2017-07-29 CN CN202311585294.4A patent/CN117903316A/zh active Pending
- 2017-07-29 KR KR1020237022677A patent/KR20230107408A/ko not_active Ceased
- 2017-07-29 ES ES17754531T patent/ES3004039T3/es active Active
-
2022
- 2022-02-14 JP JP2022020324A patent/JP2022084583A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN110088133B (zh) | 2023-12-08 |
| US20240018268A1 (en) | 2024-01-18 |
| JP2019527553A (ja) | 2019-10-03 |
| KR20230107408A (ko) | 2023-07-14 |
| ES3004039T3 (en) | 2025-03-11 |
| EP3491024A2 (fr) | 2019-06-05 |
| AU2017301887A1 (en) | 2019-02-07 |
| BR112019001327A2 (pt) | 2019-04-30 |
| RU2019105532A (ru) | 2020-08-28 |
| MX2019001184A (es) | 2019-09-26 |
| CN117903316A (zh) | 2024-04-19 |
| KR102553195B1 (ko) | 2023-07-07 |
| JP2022084583A (ja) | 2022-06-07 |
| CA3031734A1 (fr) | 2018-02-01 |
| WO2018023100A3 (fr) | 2018-03-08 |
| WO2018023100A2 (fr) | 2018-02-01 |
| RU2019105532A3 (fr) | 2020-10-22 |
| EP3491024B1 (fr) | 2024-12-18 |
| JP7062640B2 (ja) | 2022-05-06 |
| KR20190044626A (ko) | 2019-04-30 |
| CN110088133A (zh) | 2019-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA49823A (fr) | Anticorps dirigés contre pd-l1 | |
| MA49034A (fr) | Anticorps anti-lag3 | |
| MA47694A (fr) | Anticorps anti-tigit | |
| EP3498840A4 (fr) | Anticorps anti-lag-3 | |
| FR25C1022I2 (fr) | Anticorps anti-pd-1 | |
| MA47268A (fr) | Anticorps anti-gpc3 | |
| EP3423089A4 (fr) | Anticorps anti-tigit | |
| MA46041A (fr) | Anticorps anti-tim -3 | |
| MA45231A (fr) | Anticorps anti-ige | |
| MA46057A (fr) | Anticorps anti-ctla4 | |
| EP3387442A4 (fr) | Anticorps anti-cd73 humanisés | |
| EP3334757A4 (fr) | Anticorps anti-tigit | |
| EP3507307A4 (fr) | Anticorps bispécifiques | |
| EP3297671A4 (fr) | Anticorps anti-ror1 | |
| MA45004A (fr) | Anticorps spécifiques anti-wt1-hla | |
| MA53297A (fr) | Anticorps anti-icos | |
| IL263764A (en) | Anti-cd19 antibody formulations | |
| MA44236A (fr) | Anticorps anti-tgfbêta 2 | |
| EP3492591A4 (fr) | Anticorps anti-b7-h4 | |
| DK3525830T3 (da) | Pyrrolobenzodiazepin-konjugater | |
| EP3526247A4 (fr) | Anticorps anti-il1-rap | |
| EP3383915A4 (fr) | Anticorps anti-pd-1 | |
| EP3617231A4 (fr) | Anticorps anti-gpc-1 | |
| EP3399992A4 (fr) | Anticorps autoréticulants | |
| EP3484919A4 (fr) | Anticorps anti-bêta-amyloïde |